What is Spark Therapeutics'stock price?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $113.57. How much money does Spark Therapeutics make?
What is Spark Therapeutics's PE (price/earnings) ratio?
The P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Spark Therapeutics has a P/B Ratio of 8.64.
How do I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
Will Spark Therapeutics (Spart) earnings grow in the next year?
Earnings for Spark Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.34) per share. The P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is spark Therapeutics publicly traded?
PHILADELPHIA, Jan. 30, 2015 /PRNewswire/ — Spark Therapeutics announced today the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts.
What happened to spark Therapeutics stock?
PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that NASDAQ has halted trading of its common stock.
Is Spark Energy a good stock?
Is Spark Energy a good dividend stock? Spark Energy(NASDAQ:SPKE) pays an annual dividend of $0.73 per share and currently has a dividend yield of 6.62%. SPKE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Who bought Spark Therapeutics?
Roche25, 2019 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per ...
What did Spark Therapeutics sell for?
$4.3 billionThe Federal Trade Commission and European regulators cleared Roche's proposed $4.3 billion purchase of Spark Therapeutics, paving the way for its acquisition of the Philadelphia gene therapy pioneer to be completed Tuesday. Roche entered into an agreement to buy Spark (NASDAQ: ONCE) in February.
What is the stock symbol for Spark Therapeutics?
What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
Is spark owned by Roche?
Spark Therapeutics Inc. Spark Therapeutics was founded in 2013 and became a Member of the Roche Group in 2019.
How many employees does spark therapeutics have?
Spark TherapeuticsTypeSubsidiary of Hoffmann-La RocheTotal equity$496 million (2018)Number of employees368 (2019)ParentHoffmann-La RocheWebsitesparktx.com9 more rows
What kind of company is spark Therapeutics?
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
How can I invest in spark?
How to buy shares in Spark EnergyCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
What is the company Spark?
SPARK is a Staffing and Recruitment Firm for Luxury Retail including: Cosmetics, Liquor Tobacco and Confectionery as well as Luxury Goods. SPARK Business is a strategic business partner for some of the largest luxury brands.
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS...
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the following people: Mr. Jeffrey D. Marrazzo , Co-Founder, CEO & Director (Age 40) Dr. Katherine A...
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include Novozymes A/S (NVZMY) , Bio-Techne (TECH) , Qiagen (QGEN) , Qiagen (QGEN) , Neur...
What other stocks do shareholders of Spark Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA) ,...
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17....
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $113.57.
How much money does Spark Therapeutics make?
Spark Therapeutics (NASDAQ:ONCE) has a market capitalization of $4.38 billion and generates $64.72 million in revenue each year. The biotechnology...
How many employees does Spark Therapeutics have?
Spark Therapeutics employs 368 workers across the globe.
How to calculate restricted stock?
What is market capitalization for companies?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating
For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding. Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
